Key result
Rosiglitazone protected myocardium from ischemia/reperfusion injury by reducing myocardial infarction area, arrhythmia rate, and inflammatory markers compared to the I/R group.
Why the study?
Does rosiglitazone reduce myocardial ischemia/reperfusion injury in male SD rats?
Population
48 male SD rats with acute myocardial ischemia/reperfusion (I/R) injury
Comparison
Rosiglitazone (high dose and low dose) vs Control group and I/R group (no rosiglitazone)
Design
Preclinical, randomly divided
Follow-up
24 hours after I/R
Authors
Loading...
Hypothesis-generating in rat ischemia/reperfusion models; leaves open translation to human cardioprotection.
RCT (n=48)
randomly divided
Does rosiglitazone reduce myocardial ischemia/reperfusion injury in male SD rats?
Rosiglitazone protects the myocardium from ischemia/reperfusion injury in a rat model by reducing oxidative stress, inflammation, and infarct size.
Hu et al. (2014) conducted an RCT in myocardial ischemia reperfusion injury (n=48). Rosiglitazone vs. I/R group and control group was evaluated on Myocardial infarction area, arrhythmia rate, and plasma biomarkers (CK, CK-MB, hsCRP, SOD, MDA, GSH-Px, NO, ET). Rosiglitazone protected myocardium from ischemia/reperfusion injury by reducing myocardial infarction area, arrhythmia rate, and inflammatory markers compared to the I/R group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: